Concept Life Sciences, the integrated drug discovery, development and analytical services company, announced it has appointed Dr Michael Donaldson as Principal Scientist in its Dermal department and Dr Tim Calvert as VP of Business Development, Integrated Discovery Services, Europe.
Calvert has extensive experience in the delivery of integrated drug discovery and development solutions, supporting organisations ranging from virtual companies to global pharma.
Calvert joins Concept from Aptuit where he held various roles, most recently Senior Director of Integrated Drug Development, here he was responsible for executing complex and accelerated drug development programmes.
Prior to joining Aptuit, he was at Lonza, helping to secure Israel’s first gene therapy development programme, Catalent Pharma Solutions and Invitrogen.
Donaldson has more than 17 years’ experience in the pharmaceutical development and manufacturing industry. Most recently he was Director of Biology in Dermatology Therapy Area at GlaxoSmithKline (GSK).
Previous experience includes formulation and manufacturing at Stiefel, a GSK company, development of skin permeation products at MedPharm and developing liquid chromatography methods for antibiotic production analysis within the QC/QA group at Roche Pharmaceuticals.
In his new role at Concept, Donaldson will be responsible for Dermal Services.
Philip Payne, Chief Commercial Officer at Concept Life Sciences, said: “We are delighted to welcome Michael and Tim to Concept. Their notable scientific and commercial backgrounds will be invaluable in supporting the continued expansion of the group.”